These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
1251 related articles for article (PubMed ID: 16162664)
1. Comparison of beta-lactam regimens for the treatment of gram-negative pulmonary infections in the intensive care unit based on pharmacokinetics/pharmacodynamics. Burgess DS; Frei CR J Antimicrob Chemother; 2005 Nov; 56(5):893-8. PubMed ID: 16162664 [TBL] [Abstract][Full Text] [Related]
2. Pharmacodynamic target attainment of six beta-lactams and two fluoroquinolones against Pseudomonas aeruginosa, Acinetobacter baumannii, Escherichia coli, and Klebsiella species collected from United States intensive care units in 2004. DeRyke CA; Kuti JL; Nicolau DP Pharmacotherapy; 2007 Mar; 27(3):333-42. PubMed ID: 17316145 [TBL] [Abstract][Full Text] [Related]
3. Pharmacokinetic-pharmacodynamic rationale for cefepime dosing regimens in intensive care units. Roos JF; Bulitta J; Lipman J; Kirkpatrick CM J Antimicrob Chemother; 2006 Nov; 58(5):987-93. PubMed ID: 16943209 [TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetic/pharmacodynamic modeling to predict in vivo effectiveness of various dosing regimens of piperacillin/tazobactam and piperacillin monotherapy against gram-negative pulmonary isolates from patients managed in intensive care units in 2002. Frei CR; Burgess DS Clin Ther; 2008 Dec; 30(12):2335-41. PubMed ID: 19167592 [TBL] [Abstract][Full Text] [Related]
5. Pharmacodynamic modeling of intravenous antibiotics against gram-negative bacteria collected in the United States. Koomanachai P; Bulik CC; Kuti JL; Nicolau DP Clin Ther; 2010 Apr; 32(4):766-79. PubMed ID: 20435246 [TBL] [Abstract][Full Text] [Related]
6. Pharmacodynamic target attainment of seven antimicrobials against Gram-negative bacteria collected from China in 2003 and 2004. Wang H; Zhang B; Ni Y; Kuti JL; Chen B; Chen M; Nicolau DP Int J Antimicrob Agents; 2007 Nov; 30(5):452-7. PubMed ID: 17646088 [TBL] [Abstract][Full Text] [Related]
7. Continuous infusion beta-lactams for intensive care unit pulmonary infections. Frei CR; Burgess DS Clin Microbiol Infect; 2005 May; 11(5):418-21. PubMed ID: 15819874 [TBL] [Abstract][Full Text] [Related]
8. The OPTAMA programme: utilizing MYSTIC (2002) to predict critical pharmacodynamic target attainment against nosocomial pathogens in Europe. Masterton RG; Kuti JL; Turner PJ; Nicolau DP J Antimicrob Chemother; 2005 Jan; 55(1):71-7. PubMed ID: 15574471 [TBL] [Abstract][Full Text] [Related]
9. [Antimicrobial susceptibility pattern of nosocomial gram negative pathogens: results from MYSTIC study in Hacettepe University Adult Hospital (2000-2004)]. Zarakolu P; Hasçelik G; Unal S Mikrobiyol Bul; 2006 Jul; 40(3):147-54. PubMed ID: 17001842 [TBL] [Abstract][Full Text] [Related]
10. Optimising antibiotic dosing regimens based on pharmacodynamic target attainment against Pseudomonas aeruginosa collected in Hungarian hospitals. Ludwig E; Konkoly-Thege M; Kuti JL; Nicolau DP Int J Antimicrob Agents; 2006 Nov; 28(5):433-8. PubMed ID: 17046212 [TBL] [Abstract][Full Text] [Related]
11. Comparisons of parenteral broad-spectrum cephalosporins tested against bacterial isolates from pediatric patients: report from the SENTRY Antimicrobial Surveillance Program (1998-2004). Jones RN; Sader HS; Fritsche TR; Pottumarthy S Diagn Microbiol Infect Dis; 2007 Jan; 57(1):109-16. PubMed ID: 16930923 [TBL] [Abstract][Full Text] [Related]
12. Comparison of 2002-2006 OPTAMA programs for US hospitals: focus on gram-negative resistance. Crandon JL; Kuti JL; Jones RN; Nicolau DP Ann Pharmacother; 2009 Feb; 43(2):220-7. PubMed ID: 19193582 [TBL] [Abstract][Full Text] [Related]
13. Trends in antimicrobial susceptibility of Gram-negative isolates from a paediatric intensive care unit in Warsaw: results from the MYSTIC programme (1997-2007). Patzer JA; Dzierzanowska D; Turner PJ J Antimicrob Chemother; 2008 Aug; 62(2):369-75. PubMed ID: 18445575 [TBL] [Abstract][Full Text] [Related]
14. In vitro activity of newer broad spectrum beta-lactam antibiotics against enterobacteriaceae and non-fermenters: a report from Austrian intensive care units. Austrian Carbapenem Susceptibility Surveillance Group. Krause R; Mittermayer H; Feierl G; Allerberger F; Wendelin I; Hirschl A; Reisinger EC Wien Klin Wochenschr; 1999 Jul; 111(14):549-54. PubMed ID: 10467641 [TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamic profiling of intravenous antibiotics against prevalent Gram-negative organisms across the globe: the PASSPORT Program-Asia-Pacific Region. Roberts JA; Kwa A; Montakantikul P; Gomersall C; Kuti JL; Nicolau DP Int J Antimicrob Agents; 2011 Mar; 37(3):225-9. PubMed ID: 21168997 [TBL] [Abstract][Full Text] [Related]
16. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study]. Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074 [TBL] [Abstract][Full Text] [Related]
17. [Continuous surveillance of antimicrobial resistance among nosocomial gram-negative bacilli from intensive care units in China]. Chen MJ; Wang H; Zhonghua Yi Xue Za Zhi; 2003 Mar; 83(5):375-81. PubMed ID: 12820912 [TBL] [Abstract][Full Text] [Related]
18. Comparative pharmacodynamics for intravenous antibiotics against Gram-negative bacteria in Europe between 2002 and 2006: a report from the OPTAMA program. Koomanachai P; Crandon JL; Kuti JL; Nicolau DP Int J Antimicrob Agents; 2009 Apr; 33(4):348-53. PubMed ID: 19091515 [TBL] [Abstract][Full Text] [Related]
19. [Four years of monitoring of antibiotic sensitivity rates of Pseudomonas aeruginosa and Acinetobacter baumannii strains isolated from patients in intensive care unit and inpatient clinics]. Alişkan H; Colakoğlu S; Turunç T; Demiroğlu YZ; Erdoğan F; Akin S; Arslan H Mikrobiyol Bul; 2008 Apr; 42(2):321-9. PubMed ID: 18697430 [TBL] [Abstract][Full Text] [Related]
20. Use of Monte Carlo simulation to assess the pharmacodynamics of beta-lactams against Pseudomonas aeruginosa infections in children: a report from the OPTAMA program. Ellis JM; Kuti JL; Nicolau DP Clin Ther; 2005 Nov; 27(11):1820-30. PubMed ID: 16368453 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]